Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo Sells 10,780 Shares

Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo sold 10,780 shares of the company’s stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $8.56, for a total value of $92,276.80. Following the transaction, the chief financial officer now owns 319,650 shares of the company’s stock, valued at approximately $2,736,204. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Thomas Catinazzo also recently made the following trade(s):

• On Thursday, June 27th, Thomas Catinazzo sold 9,373 shares of Relay Therapeutics stock. The shares were sold at an average price of $6.24, for a total value of $58,487.52.

Relay Therapeutics Price Performance

Relay Therapeutics stock opened at $8.22 on Thursday. Relay Therapeutics, Inc. has a one year low of $5.70 and a one year high of $12.63. The stock has a market capitalization of $1.09 billion, a PE ratio of -3.11 and a beta of 1.66. The business’s fifty day moving average is $7.39 and its 200 day moving average is $8.02.

Relay Therapeutics (NASDAQ:RLAY) last released its quarterly earnings data on Thursday, May 2nd. The company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.70) by $0.08. The business had revenue of $10.01 million for the quarter, compared to analysts’ expectations of $0.12 million. During the same period last year, the business earned ($0.78) earnings per share. The company’s quarterly revenue was up 4327.9% on a year-over-year basis. As a group, sell-side analysts expect that Relay Therapeutics, Inc. will post -2.81 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Caxton Associates LP lifted its holdings in Relay Therapeutics by 637.3% in the fourth quarter. Caxton Associates LP now owns 279,101 shares of the company’s stock valued at $3,073,000 after acquiring an additional 241,247 shares during the period. Russell Investments Group Ltd. raised its stake in shares of Relay Therapeutics by 57.2% in the first quarter. Russell Investments Group Ltd. now owns 179,972 shares of the company’s stock worth $1,494,000 after buying an additional 65,484 shares during the period. Finepoint Capital LP raised its stake in shares of Relay Therapeutics by 51.3% in the fourth quarter. Finepoint Capital LP now owns 1,317,870 shares of the company’s stock worth $14,510,000 after buying an additional 447,000 shares during the period. BVF Inc. IL raised its stake in shares of Relay Therapeutics by 67.8% in the fourth quarter. BVF Inc. IL now owns 3,970,045 shares of the company’s stock worth $43,710,000 after buying an additional 1,604,240 shares during the period. Finally, Norges Bank bought a new position in shares of Relay Therapeutics in the fourth quarter worth about $33,789,000. Institutional investors own 96.98% of the company’s stock.

Analyst Upgrades and Downgrades

RLAY has been the subject of a number of research reports. Barclays decreased their price objective on Relay Therapeutics from $15.00 to $14.00 and set an “overweight” rating for the company in a report on Friday, July 26th. JMP Securities cut their target price on Relay Therapeutics from $24.00 to $21.00 and set a “market outperform” rating on the stock in a research note on Thursday, July 18th. Oppenheimer reissued an “outperform” rating and issued a $25.00 target price (down from $33.00) on shares of Relay Therapeutics in a research note on Monday, May 6th. Finally, HC Wainwright cut their target price on Relay Therapeutics from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Wednesday, July 17th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $21.60.

About Relay Therapeutics

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.